QNRX first FDA-approved treatment for Netherton Syndrome

Quoin Pharmaceuticals (NASDAQ: QNRX ) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.

This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome.

JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. ( QNRX ) with a Market Outperform rating and a price target of 8usd.

QNRX is massively oversold having a bullish divergence chart formation and fundamentals that can skyrocket the price to 12 usd in my opinion!

Could be a Great buy opportunity at $1.91 today!